447 research outputs found

    Моделирование энергопотребления зданий: оценка статической и динамической моделей

    Full text link
    The aim of the present paper is to show recent results obtained in modeling the building system, presenting a review on the common numerical models used to estimate the energy consumptions. In particular, both steady-state and dynamic models are investigated by analyzing their main assumptions, limitations and fields of usage. As a matter of fact, the most common models are based on steady state approaches, but new technologies and the need to implement innovative regulation criteria for heating and cooling systems by performing detailed coupled studies on the building and heating/cooling systems, push towards the use of dynamic tools with low computational costs. Therefore, the use of dynamic models is often suggested, especially when different building configurations are investigated (as e. g. in the design stage or for a renovation perspective). Starting from this point, sensitive analyses on the installation of a proper insulation in the building envelope is then presented.Цель данной работы — показать последние результаты, полученные при моделировании системы здания, с описанием общих численных моделей, используемых для оценки энергопотребления. В частности на статических и динамических моделях исследованы основные допущения, ограничения и область использования путем их анализа. Собственно говоря, наиболее распространенные модели основаны на установившихся подходах, но новые технологии и необходимость внедрения для систем отопления и холодоснабжения инновационных критериев регулирования с использованием подробного анализа здания и систем отопления/охлаждения, подталкивают к использованию динамических инструментов с низкими вычислительными затратами. Таким образом, часто целесообразно использование динамических моделей, особенно когда существуют разные конфигурации здания (как, например, в стадии проектирования или для перспективной реконструкции). В статье представлен анализ установки правильного утеплителя в ограждающих конструкциях

    Local recurrence of soft tissue sarcoma: A radiomic analysis

    Get PDF
    Background To perform a radiomics analysis in local recurrence (LR) surveillance of limb soft tissue sarcoma (STS) Patients and methods This is a sub-study of a prospective multicenter study with Institutional Review Board approval supported by ESSR (European Society of Musculoskeletal Radiology). radiomics analysis was done on fast spin echo axial T1w, T2w fat saturated and post-contrast T1w (T1wGd) 1.5T MRI images of consecutively recruited patients between March 2016 and September 2018. Results N = 11 adult patients (6 men and 5 women; mean age 57.8 \ub1 17.8) underwent MRI to exclude STS LR: a total of 33 follow-up events were evaluated. A total of 198 data-sets per patients of both pathological and normal tissue were analyzed. Four radiomics features were significantly correlated to tumor size (p < 0.02) and four radiomics features were correlated with grading (p < 0.05). ROC analysis showed an AUC between 0.71 (95%CI: 0.55-0.87) for T1w and 0.96 (95%CI: 0.87-1.00) for post-contrast T1w. Conclusions radiomics features allow to differentiate normal tissue from pathological tissue in MRI surveillance of local recurrence of STS. radiomics in STS evaluation is useful not only for detection purposes but also for lesion characterization

    Splitting the solar radiation in direct and diffuse components; Insights and constrains on the clearness-diffuse fraction representation

    Get PDF
    open3noIn many engineering applications, it is mandatory to know separately the solar radiation diffuse and direct components. Examples regard the assessment of the energy potentially exploitable by a system of solar thermal or photovoltaic panels and, in general, all the cases where it is necessary to calculate the radiative solar power collected by a surface. In fact, radiation components will differently project on the surface of interest and will weigh in a different manner, depending on the surface orientation, in the computation of the effective incident radiation. To perform this decomposition starting from data relative to a horizontal plane, two non-dimensional quantities, namely, the diffuse fraction, kd, and the clearness, kt, are usually put in mutual relation by correlating experimental data on a graphical ground rather than using physical considerations. In the present study, some insights are given on the shape of this correlation starting from geometric and physical considerations. It is shown that many results and graphs presented in literature have not physical meaning; rather they are simply artifacts due to geometrical or other constraints. These evidences open the way to a new approach to solar radiation decomposition founded on physical-based correlations.openScarpa, F.*; Marchitto, A.; Tagliafico, L.A.Scarpa, F.; Marchitto, A.; Tagliafico, L. A

    Ivar, an interpretation‐oriented tool to manage the update and revision of variant annotation and classification

    Get PDF
    The rapid evolution of Next Generation Sequencing in clinical settings, and the resulting challenge of variant reinterpretation given the constantly updated information, require robust data management systems and organized approaches. In this paper, we present iVar: a freely available and highly customizable tool with a user‐friendly web interface. It represents a platform for the unified management of variants identified by different sequencing technologies. iVar accepts variant call format (VCF) files and text annotation files and elaborates them, optimizing data organization and avoiding redundancies. Updated annotations can be periodically re‐uploaded and associated with variants as historically tracked attributes, i.e., modifications can be recorded whenever an updated value is imported, thus keeping track of all changes. Data can be visualized through variant‐centered and sample‐centered interfaces. A customizable search function can be exploited to periodically check if pathogenicity‐related data of a variant has changed over time. Patient recontacting ensuing from variant reinterpretation is made easier by iVar through the effective identification of all patients present in the database carrying a specific variant. We tested iVar by uploading 4171 VCF files and 1463 annotation files, obtaining a database of 4166 samples and 22,569 unique variants. iVar has proven to be a useful tool with good performance in terms of collecting and managing data from a medium‐throughput laboratory

    preliminary investigation on a rotary magnetocaloric refrigerator prototype

    Get PDF
    Abstract Environmental legislations are currently imposing important restrictions to regulate the use of refrigerant fluids in order to reduce the greenhouse gases emissions and global warming potential. To overcome these issues, a valid alternative to replace conventional refrigeration systems can be represented by magnetic refrigeration. Since magnetic refrigeration is based on the magnetocaloric effect it represents an environmental friendly technology that avoids the use of Chlorinated refrigerants. In this paper a preliminary analysis of a novel magnetocaloric refrigerator is presented. The magnetocaloric refrigeration prototype uses Gadolinium as refrigerant and water as heat exchange medium, and relies on permanent magnets as magnetic field source. The device operates according to the active regenerative principle with a rotary movement. A detailed description of the main components included in the design of the prototype device is presented along with a schematic representation of the hydraulic circuit. Focusing on the regenerators beds, some simulations have been carried out to quantify the heat energy fluxes between water and gadolinium. The results of the simulations show a decrease on gadolinium temperature distribution cycle by cycle highlighting the actual effect of the regeneration

    A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation

    Get PDF
    Background: In early-stage HER2-positive breast cancer, escalation or de-escalation of systemic therapy is a controversial topic. As an aid to treatment decisions, we aimed to develop a prognostic assay that integrates multiple data types for predicting survival outcome in patients with newly diagnosed HER2-positive breast cancer. Methods: We derived a combined prognostic model using retrospective clinical–pathological data on stromal tumour-infiltrating lymphocytes, PAM50 subtypes, and expression of 55 genes obtained from patients who participated in the Short-HER phase 3 trial. The trial enrolled patients with newly diagnosed, node-positive, HER2-positive breast cancer or, if node negative, with at least one risk factor (ie, tumour size >2 cm, histological grade 3, lymphovascular invasion, Ki67 >20%, age ≤35 years, or hormone receptor negativity), and randomly assigned them to adjuvant anthracycline plus taxane-based combinations with either 9 weeks or 1 year of trastuzumab. Trastuzumab was administered intravenously every 3 weeks (8 mg/kg loading dose at first cycle, and 6 mg/kg thereafter) for 18 doses or weekly (4 mg/kg loading dose in the first week, and 2 mg/kg thereafter) for 9 weeks, starting concomitantly with the first taxane dose. Median follow-up was 91·4 months (IQR 75·1–105·6). The primary objective of our study was to derive and evaluate a combined prognostic score associated with distant metastasis-free survival (the time between randomisation and distant recurrence or death before recurrence), an exploratory endpoint in Short-HER. Patient samples in the training dataset were split into a training set (n=290) and a testing set (n=145), balancing for event and treatment group. The training set was further stratified into 100 iterations of Monte-Carlo cross validation (MCCV). Cox proportional hazard models were fit to MCCV training samples using Elastic-Net. A maximum of 92 features were assessed. The final prognostic model was evaluated in an independent combined dataset of 267 patients with early-stage HER2-positive breast cancer treated with different neoadjuvant and adjuvant anti-HER2-based combinations and from four other studies (PAMELA, CHER-LOB, Hospital Clinic, and Padova) with disease-free survival outcome data. Findings: From Short-HER, data from 435 (35%) of 1254 patients for tumour size (T1 vs rest), nodal status (N0 vs rest), number of tumour-infiltrating lymphocytes (continuous variable), subtype (HER2-enriched and basal-like vs rest), and 13 genes composed the final model (named HER2DX). HER2DX was significantly associated with distant metastasis-free survival as a continuous variable (p<0·0001). HER2DX median score for quartiles 1–2 was identified as the cutoff to identify low-risk patients; and the score that distinguished quartile 3 from quartile 4 was the cutoff to distinguish medium-risk and high-risk populations. The 5-year distant metastasis-free survival of the low-risk, medium-risk, and high-risk populations were 98·1% (95% CI 96·3–99·9), 88·9% (83·2–95·0), and 73·9% (66·0–82·7), respectively (low-risk vs high-risk hazard ratio [HR] 0·04, 95% CI 0·0–0·1, p<0·0001). In the evaluation cohort, HER2DX was significantly associated with disease-free survival as a continuous variable (HR 2·77, 95% CI 1·4–5·6, p=0·0040) and as group categories (low-risk vs high-risk HR 0·27, 0·1–0·7, p=0·005). 5-year disease-free survival in the HER2DX low-risk group was 93·5% (89·0–98·3%) and in the high-risk group was 81·1% (71·5–92·1). Interpretation: The HER2DX combined prognostic score identifies patients with early-stage, HER2-positive breast cancer who might be candidates for escalated or de-escalated systemic treatment. Future clinical validation of HER2DX seems warranted to establish its use in different scenarios, especially in the neoadjuvant setting. Funding: Instituto Salud Carlos III, Save the Mama, Pas a Pas, Fundación Científica, Asociación Española Contra el Cáncer, Fundación SEOM, National Institutes of Health, Agenzia Italiana del Farmaco, International Agency for Research on Cancer, and the Veneto Institute of Oncology, and Italian Association for Cancer Research

    Allele specific CRISPR/Cas9 editing of dominant Epidermolysis Bullosa Simplex in human epidermal stem cells

    Get PDF
    : Epidermolysis Bullosa Simplex (EBS) is a rare skin disease inherited mostly in an autosomal dominant manner. Patients display a skin fragility that leads to blisters and erosions caused by minor mechanical trauma. EBS phenotypic and genotypic variants are caused by genetic defects in intracellular proteins whose function is to provide the attachment of basal keratinocytes to the basement membrane zone and most of EBS cases display mutations in keratin 5 (KRT5) and keratin 14 (KRT14) genes. Besides palliative treatments, there is still no long-lasting effective cure to correct the mutant gene and abolish dominant negative effect of the pathogenic protein over its wild-type counterpart. Here, we propose a molecular strategy for EBS01 patient's keratinocytes carrying a monoallelic c.475/495del21 mutation in KRT14 exon1. Through the CRISPR/Cas9 system we performed a specific cleavage only on the mutant allele and restore a normal cellular phenotype and a correct intermediate filament network, without affecting the epidermal stem cell, referred to as holoclones, which play a crucial role in epidermal regeneration
    corecore